Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
71
AGL Quote, Financials, Valuation and Earnings
Last price:
$0.99
Seasonality move
:
41.59%
Day range:
$0.88 - $1.00
52-week range:
$0.51 - $6.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.07x
P/B ratio:
1.34x
Volume:
14.3M
Avg. volume:
6.9M
1-year change:
-54.7%
Market cap:
$411.3M
Revenue:
$6.1B
EPS (TTM):
-$0.78
Analysts' Opinion
-
Consensus RatingAgilon Health, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 13 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $0.99, Agilon Health, Inc. has an estimated downside of -0.63% from its current price of $0.99.
-
Price Target UpsideAccording to analysts, the highest upside price target is $2.00 representing 101.59% upside increase from its current price of $0.99.
Fair Value
-
According to the consensus of 15 analysts, Agilon Health, Inc. has -0.63% downside to fair value with a price target of $0.99 per share.
AGL vs. S&P 500
-
Over the past 5 trading days, Agilon Health, Inc. has overperformed the S&P 500 by 45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Agilon Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Agilon Health, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Agilon Health, Inc. reported revenues of $1.4B.
Earnings Growth
-
Agilon Health, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Agilon Health, Inc. reported earnings per share of -$0.27.
Enterprise value:
137.6M
EV / Invested capital:
--
Price / LTM sales:
0.07x
EV / EBIT:
--
EV / Revenue:
0.02x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-1.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$135.7M
Return On Assets:
-17.81%
Net Income Margin (TTM):
-5.49%
Return On Equity:
-71.4%
Return On Invested Capital:
-65.38%
Operating Margin:
-8.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.9B | $5.6B | $5.9B | $1.5B | $1.4B | |
| Gross Profit | $166.4M | -$74.5M | -$135.7M | -$70.4M | -$75.1M | |
| Operating Income | -$124.7M | -$343.6M | -$369.3M | -$132.1M | -$127.2M | |
| EBITDA | -$109.4M | -$320.9M | -$341.2M | -$125.8M | -$119.8M | |
| Diluted EPS | -$0.22 | -$0.82 | -$0.78 | -$0.28 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5B | $1.6B | $2B | $1.8B | $1.3B | |
| Total Assets | $1.7B | $1.9B | $2.3B | $2.1B | $1.6B | |
| Current Liabilities | $422.8M | $658.2M | $1.3B | $1.4B | $1.2B | |
| Total Liabilities | $557.7M | $785.1M | $1.4B | $1.5B | $1.3B | |
| Total Equity | $1.1B | $1.1B | $871.6M | $574.9M | $306.1M | |
| Total Debt | $56.9M | $55M | $51.8M | $43.9M | $2.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$145M | -$135.4M | -$68.8M | -$7.7M | -$18.2M | |
| Cash From Investing | -$49.8M | $114M | $89.7M | $46.6M | $18.7M | |
| Cash From Financing | -$191.2M | -$3.4M | -$3M | -$1.4M | -$236K | |
| Free Cash Flow | -$168.7M | -$179.6M | -$114.6M | -$12.2M | -$34.7M | |
AGL
Sector
Market Cap
$411.3M
$28.3M
Price % of 52-Week High
16.32%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
1.13%
-1.59%
1-Year Price Total Return
-54.7%
-17.41%
Beta (5-Year)
--
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.79
200-day SMA
Sell
Level
$1.88
Bollinger Bands (100)
Buy
Level
0.68 - 1.14
Chaikin Money Flow
Sell
Level
-132.5M
20-day SMA
Buy
Level
$0.73
Relative Strength Index (RSI14)
Buy
Level
72.36
ADX Line
Buy
Level
19.01
Williams %R
Sell
Level
-1.3665
50-day SMA
Buy
Level
$0.70
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Sell
Level
-364.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2571)
Sell
CA Score
(Annual)
Level (-0.6287)
Buy
Beneish M-Score
(Annual)
Level (-6.1261)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.1754)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.
Stock Forecast FAQ
In the current month, AGL has received 2 Buy ratings 13 Hold ratings, and 0 Sell ratings. The AGL average analyst price target in the past 3 months is $0.99.
-
Where Will Agilon Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Agilon Health, Inc. share price will drop to $0.99 per share over the next 12 months.
-
What Do Analysts Say About Agilon Health, Inc.?
Analysts are divided on their view about Agilon Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Agilon Health, Inc. is a Sell and believe this share price will rise from its current level to $0.25.
-
What Is Agilon Health, Inc.'s Price Target?
The price target for Agilon Health, Inc. over the next 1-year time period is forecast to be $0.99 according to 15 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 13 analysts rate the stock a Hold.
-
Is AGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Agilon Health, Inc. is a Hold. 13 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AGL?
You can purchase shares of Agilon Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Agilon Health, Inc. shares.
-
What Is The Agilon Health, Inc. Share Price Today?
Agilon Health, Inc. was last trading at $0.99 per share. This represents the most recent stock quote for Agilon Health, Inc.. Yesterday, Agilon Health, Inc. closed at $0.99 per share.
-
How To Buy Agilon Health, Inc. Stock Online?
In order to purchase Agilon Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AGL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AGL
Sector
P/E ratio
--
24.24x
PEG ratio
-0.03x
-0.01x
P/B ratio
1.34x
1.84x
Price / LTM sales
0.07x
1.60x
Growth Metrics
AGL
Sector
Revenue growth
-1.08%
4.6%
Earnings growth
6.01%
10.71%
Revenue (5-year growth)
50.14%
6.45%
Earnings forecast
-$0.27
-$0.19
Profitability
AGL
Sector
Profitability FY 2024
-$19.6M
$3.5M
Return on invested capital
-65.38%
-32.04%
Return on assets
-17.81%
-28.44%
Return on equity
-71.4%
-38.09%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
AGL
Sector
Total cash
$310.9M
$26.1M
Short term investments
$211.7M
$25.7M
Total assets
$1.7B
$76.4M
Long term debt
$2.2M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
